Research Article
Bacterial FtsZ inhibition by benzo[d]imidazole-2-carboxamide derivative with anti-TB activity
Published Online:14 Sep 2022https://doi.org/10.4155/fmc-2022-0120
Abstract
Aims: The present study aimed to assess the mode of action of previously reported anti-Mycobacterium tuberculosis benzo[d]imidazole-2-carboxamides against FtsZ along with their antibacterial potential. Materials & methods: The anti-mycobacterial action of benzo[d]imidazole-2-carboxamides against FtsZ was evaluated using inhibition of Bacillus subtilis 168, light scattering assay, circular dichroism spectroscopy, in silico molecular docking and molecular dynamics simulations. Results & conclusion: Three compounds (1k, 1o and 1e) were active against isoniazid-resistant strains. Four compounds (1h, 1i, 1o and 4h) showed >70% inhibition against B. subtilis 168. Compound 1o was the most potent inhibitor (91 ± 5% inhibition) of B. subtilis 168 FtsZ and perturbed its secondary structure. Molecular docking and molecular dynamics simulation of complexed 1o suggested M. tuberculosis FtsZ as a possible target for antitubercular activity.
Graphical abstract
Keywords:
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Robert Koch: A Life in Medicine and Bacteriology. Science Tech Publishers, WI, USA (Accessed on 18 Dec 2017).
- 2. . Global tuberculosis report 2021 (2021). www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
- 3. . Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives. Curr. Med. Chem. 22, 4379–4397 (2015).
- 4. . Tuberculosis. Lancet 387, 1211–1226 (2015).
- 5. . New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology 24, 86–98 (2018).
- 6. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR–Mycobacterium tuberculosis strains. Front. Cell. Infect. Microbiol. 8, 114 (2018).
- 7. Synthesis, biological evaluation and structure-activity relationship of 2-styrylquinazolones as anti-tubercular agents. Bioorg. Med. Chem. Lett. 26, 2663–2669 (2016).
- 8. . Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads. Bioorg. Med. Chem. Lett. 26, 5960–5966 (2016).
- 9. . α-Sulfonamidophosphonates as new anti-mycobacterial chemotypes: design, development of synthetic methodology, and biological evaluation. Bioorg. Chem. 82, 246–252 (2019).
- 10. Benzimidazoquinazolines as new potent anti-TB chemotypes: design, synthesis, and biological evaluation. Bioorg. Chem. 99, 103774 (2020).
- 11. N-arylalkylbenzo[d]thiazole-2-carboxamides as anti-mycobacterial agents: design, new methods of synthesis and biological evaluation. Med. Chem. Commun. 5, 1489–1495 (2014).
- 12. Benzo[d]thiazol-2-yl(piperazin-1-yl)methanones as new anti-mycobacterial chemotypes: design, synthesis, biological evaluation and 3D-QSAR studies. Eur. J. Med. Chem. 116, 187–199 (2016).
- 13. Benzo[d]thiazole-2-carbanilides as new anti-TB chemotypes: design, synthesis, biological evaluation, and structure–activity relationship. Eur. J. Med. Chem. 155, 364–380 (2018).
- 14. . FtsZ: a novel target for tuberculosis drug discovery. Curr. Top. Med. Chem. 7, 527–543 (2007).
- 15. Novel trisubstituted benzimidazoles, targeting MtbFtsZ, as a new class of antitubercular agents. J. Med. Chem. 54, 374–381 (2011).
- 16. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg. Med. Chem. 21, 3318–3326 (2013).
- 17. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents. Bioorg. Med. Chem. 22, 2602–2612 (2014).
- 18. Structure–activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting Mtb-FtsZ as antitubercular agents. RSC Med. Chem. 12, 78–94 (2021).
- 19. . Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ. Bioorg. Med. Chem. 24, 6354–6369 (2016).
- 20. . Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin. Ther. Pat. 21, 657–679 (2011).
- 21. Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents. Bioorg. Chem. 107, 104538 (2021). • Original study on benzo[d]imidazole-2-carboxamides as antitubercular agents.
- 22. . Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41, 1004–1009 (1997).
- 23. Improving the production of AHL lactonase AiiO-AIO6 from Ochrobactrum sp. M231 in intracellular protease-deficient Bacillus subtilis. AMB Express 10, 138 (2020).
- 24. SB-RA-2001 inhibits bacterial proliferation by targeting FtsZ assembly. Biochemistry 53, 2979–2992 (2014).
- 25. . A rhodanine derivative CCR-11 inhibits bacterial proliferation by inhibiting the assembly and GTPase activity of FtsZ. Biochemistry 51, 5434–5442 (2012).
- 26. . Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175 (2008).
- 27. . Purification and assembly of FtsZ. Methods Enzymol. 298, 305–313 (1998). • Discusses the origin of BsFtsZ of the recombinant protein adopted for expression and purification.
- 28. . Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal. Biochem. 287, 252–260 (2000).
- 29. . 2Q1Y: crystal structure of cell division protein FtsZ from Mycobacterium tuberculosis in complex with GTP-gamma-S. www.rcsb.org/structure/2q1y
- 30. . Structure of Mycobacterium tuberculosis FtsZ reveals unexpected, G protein-like conformational switches. J. Mol. Biol. 342, 953–970 (2004). •• Discusses the only available co-crystallized structure of MtbFtsZ with non-hydrolyzable GTP-γ-S.
- 31. . Structural insights into the conformational variability of FtsZ. J. Mol. Biol. 373, 1229–1242 (2007).
- 32. . www.rcsb.org/
- 33. . DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics 28, 2074–2075 (2012).
- 34. . Open Babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).
- 35. . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comb. Chem. 31, 455–461 (2010).
- 36. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).
- 37. . The PyMOL Molecular Genetics Graphics System. DeLano Scientific LLC, CA, USA (2002).
- 38. . LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011).
- 39. . GROMACS 2020.4 manual (2020). http://doi.org/10.5281/zenodo.4054996
- 40. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 (2015).
- 41. . Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012).
- 42. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671–690 (2010).
- 43. . Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J. Comput. Chem. 33, 2451–2468 (2012).
- 44. . SAR studies on trisubstituted benzimidazoles as inhibitors of MtbFtsZ for the development of novel antitubercular agents. J. Med. Chem. 56, 9756–9770 (2013).
- 45. . BT-benzo-29 inhibits bacterial cell proliferation by perturbing FtsZ assembly. FEBS J. 282(20), 4015–4033 (2015).
- 46. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31, 3497–3500 (2003).
- 47. . FtsZ regulates frequency of cell division in Escherichia coli. J. Bacteriol. 172, 2765–2768 (1990).
- 48. . FtsZ is an essential cell division gene in Escherichia coli. J. Bacteriol. 173, 3500–3506 (1991).
- 49. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673–1675 (2008). •• Discusses the bactericidal potential of PC190723 through inhibition of FtsZ and cell division.
- 50. . Multiple effects of benzamide antibiotics on FtsZ function. Mol. Microbiol. 80, 68–84 (2011).
- 51. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278, 21972–21979 (2003).
- 52. . Linezolid: a promising option in the treatment of gram-positives. J. Antimicrob. Chemother. 72, 354–364 (2017).
- 53. . Tuberculosis. In: Handbook of Anti-Tuberculosis Agents. NY, USA, 122–125 (2008).
- 54. . Targeting the assembly of bacterial cell division protein FtsZ with small molecules. ACS Chem. Biol. 7, 269–277 (2012).
- 55. . Exploring the possible binding mode of trisubstituted benzimidazoles analogues in silico for novel drug design targeting Mtb FtsZ. Med. Chem. Res. 26, 153–169 (2017). • Discussion of the binding of benzimidazole based MtbFtsZ inhibitors to its allosteric site.
- 56. . Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ. J. Fluor. Chem. 196, 44–56 (2017). •• Critical review that includes the binding site of benzimidazoles in MtbFtsZ.
- 57. . Identification of antimycobacterial agent using in silico virtual screening, ADME prediction, docking, and molecular dynamics simulations approach. Curr. Comput. Aided Drug Des. 17, 806–816 (2021).
- 58. . Molecular dynamics simulations and drug discovery. BMC Biol. 9, 71 (2011).
- 59. . Molecular dynamics simulations: advances and applications. Adv. Appl. Bioinform. Chem. 8, 37–47 (2015).
- 60. . Molecular dynamics simulation for all. Neuron 99, 1129–1143 (2018).
